Skip to main content
. 2023 Jun 1;19(6):e1010770. doi: 10.1371/journal.pgen.1010770

Fig 8. Clock dysfunction diminishes the chemotherapeutic cell death response.

Fig 8

KPC wildtype (WT) and KPC-BKO cells (n = 3) were treated with increasing doses of gemcitabine and paclitaxel. Fold change differences (± standard error) in Caspase 3/7 activity in response to either A. gemcitabine or B. paclitaxel. Fold change differences (± standard error) in dead-cell protease activity in response to C. gemcitabine or D. paclitaxel. Comparisons between conditions at each concentration were made with t-test. [ns = not significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001].